Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6168232 | Urology | 2012 | 6 Pages |
Abstract
Tanezumab might improve symptoms for some patients with chronic prostatitis/chronic pelvic pain syndrome. Although proof of concept was not demonstrated in the present study, additional studies with larger populations and stricter inclusion criteria according to patient phenotype might identify populations in which antinerve growth factor treatment will provide clinical benefit.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
J. Curtis Nickel, Gary Atkinson, John N. Krieger, Ian W. Mills, Michel Pontari, Daniel A. Shoskes, Tim J. Crook,